B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

24.32 -0.21 (-0.86%)
Streaming Delayed Price Updated: 12:46 PM EDT, Apr 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Beats Q2 2025 Revenue Estimates and Posts Narrower Loss Than Expected ↗
Arcutis Biotherapeutics (ARQT) beats Q2 2025 revenue and EPS estimates with $81.5M in sales, driven by strong ZORYVE demand. Shares rise post-earnings. 
Via Chartmill
News headline image
Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis ↗
Arcutis will present five posters at RAD 2025 featuring long-term safety and efficacy data for Zoryve cream in children with eczema. 
Via Benzinga
News headline image
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
A Glimpse Into The Expert Outlook On Arcutis Biotherapeutics Through 5 Analysts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 25, 2025 ↗
 
Via Benzinga
News headline image
Analyst Expectations For Arcutis Biotherapeutics's Future ↗
 
Via Benzinga
News headline image
Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Would Mark Minervini consider ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) a top stock pick? ↗
A fundamental and technical analysis of (NASDAQ:ARQT): Is ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) suited for high growth investing? 
Via Chartmill
News headline image
Arcutis Announces Chief Financial Officer Transition
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Demystifying Arcutis Biotherapeutics: Insights From 9 Analyst Reviews ↗
 
Via Benzinga
News headline image
Arcutis and Padagis Agree to Stay Patent Lawsuit
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Rebound Or Fakeout? The 200-Day MA Holds The Key To The Next Big Move ↗
A discussion whether the rebound could sustain, the worst scenario and the potential target price for the S&P 500. 
Via Talk Markets
Topics Stocks Stocks / Equities
News headline image
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs ↗
 
Via Benzinga
News headline image
How does ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) stack up against Mark Minervini’s strategy? ↗
A fundamental and technical analysis of (NASDAQ:ARQT): Why ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) is Poised for High Growth. 
Via Chartmill
News headline image
Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio? ↗
Top performers last week: DGNX (108.29%), NEXT (25.07%), CELH (21.60%), SIG (21.08%), NFE (20.63%), MRP (16.61%), ARQT (16.35%), LCID (15.79%), CPRX (15.27%), STNE (14.20%). Are they in your... 
Via Benzinga
News headline image
What's Going On With Arcutis Biotherapeutics Stock Monday? ↗
Arcutis shares traded higher on Monday after Health Canada approved its Zoryve cream for the treatment of mild to moderate atopic dermatitis. 
Via Benzinga
News headline image
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally ↗
Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter. 
Via Stocktwits
News headline image
Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.